Tesamorelin research guide
Synthetic growth-hormone-releasing hormone analogue
An indication-specific evidence guide to tesamorelin, separating established pharmaceutical trials from unrelated catalogue or body-composition claims.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. Unlike many catalogue peptides, an authorised pharmaceutical form has been studied in large randomised programmes for a defined HIV-associated indication overseas. That evidence must stay tied to the studied product, population and endpoint.
02 · Evidence position
What the literature can support
Randomised human evidence is comparatively mature, but it is indication-specific and product-specific. It does not validate generic weight-management claims, compounded copies or independent research batches. A scientific page should identify this boundary prominently rather than borrowing the credibility of medicine trials.
03 · Study-level map
Evidence and its limits
What population was studied?
A 12-month randomised placebo-controlled programme evaluated tesamorelin in people with HIV-associated abdominal fat accumulation.
Limit: The population and pharmaceutical formulation were specific; the findings should not be generalised to unrelated populations or products.
Was the finding replicated?
An earlier multicentre randomised trial also measured visceral adipose tissue and metabolic endpoints in the same clinical context.
Limit: Replication within an indication still does not establish equivalence of an unapproved research material.
04 · Analytical context
Questions a batch record should answer
- 01Does the expected mass and sequence match tesamorelin rather than another GHRH analogue?
- 02Are deamidation, oxidation and truncation products considered in the stability-indicating method?
- 03Is the stated amount supported by a quantitative assay rather than inferred from fill weight or HPLC area?
05 · Boundary conditions
What this record does not establish
- Clinical evidence is limited to specified populations, products and protocols.
- An ingredient name does not demonstrate pharmaceutical equivalence.
- This page does not provide weight-loss, dosing or human-use advice.
Sources checked
- 1.Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation
PubMed / Journal of Acquired Immune Deficiency Syndromes · 2010 · Primary study
- 2.Metabolic effects of a growth hormone-releasing factor in patients with HIV
PubMed / New England Journal of Medicine · 2007 · Primary study